| |
| Names | |
|---|---|
|
Preferred IUPAC name
1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine | |
| Identifiers | |
3D model (
JSmol)
|
|
| Abbreviations | JNJ-5207852 |
| ChEMBL | |
| ChemSpider | |
| MeSH | JNJ-5207852 |
PubChem
CID
|
|
| UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
| Properties | |
| C20H32N2O | |
| Molar mass | 316.480 g/mol |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
| |
JNJ-5207852 is a histamine antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies, [1] and has been suggested as a possible treatment for some memory defects associated with epilepsy. [2] JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 was in a Phase II clinical trial for the treatment of narcolepsy in 2007. [3]
References
- ^ Barbier AJ, Berridge C, Dugovic C, et al. (November 2004). "Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist". Br. J. Pharmacol. 143 (5): 649–61. doi: 10.1038/sj.bjp.0705964. PMC 1575430. PMID 15466448.
- ^ Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K (Mar 2006). "Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice". Neuropharmacology. 50 (4): 404–11. doi: 10.1016/j.neuropharm.2005.09.017. PMID 16310812. S2CID 39844562.
- ^ Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (July 2008). "The histamine H3 receptor: an attractive target for the treatment of cognitive disorders". Br. J. Pharmacol. 154 (6): 1166–81. doi: 10.1038/bjp.2008.147. PMC 2483387. PMID 18469850.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Names | |
|---|---|
|
Preferred IUPAC name
1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine | |
| Identifiers | |
3D model (
JSmol)
|
|
| Abbreviations | JNJ-5207852 |
| ChEMBL | |
| ChemSpider | |
| MeSH | JNJ-5207852 |
PubChem
CID
|
|
| UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
| Properties | |
| C20H32N2O | |
| Molar mass | 316.480 g/mol |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
| |
JNJ-5207852 is a histamine antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies, [1] and has been suggested as a possible treatment for some memory defects associated with epilepsy. [2] JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 was in a Phase II clinical trial for the treatment of narcolepsy in 2007. [3]
References
- ^ Barbier AJ, Berridge C, Dugovic C, et al. (November 2004). "Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist". Br. J. Pharmacol. 143 (5): 649–61. doi: 10.1038/sj.bjp.0705964. PMC 1575430. PMID 15466448.
- ^ Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K (Mar 2006). "Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice". Neuropharmacology. 50 (4): 404–11. doi: 10.1016/j.neuropharm.2005.09.017. PMID 16310812. S2CID 39844562.
- ^ Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (July 2008). "The histamine H3 receptor: an attractive target for the treatment of cognitive disorders". Br. J. Pharmacol. 154 (6): 1166–81. doi: 10.1038/bjp.2008.147. PMC 2483387. PMID 18469850.
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |